Completed PHASE2 INTERVENTIONAL NCT00250393

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Placebo-Controlled , Crossover , Double-Blind Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Monotherapy]

Sponsor: Kyowa Kirin Co., Ltd.

Conditions Parkinson's Disease

Interventions Istradefylline (KW-6002)

Updated 7 times since 2017 Last updated: Aug 28, 2012 Started: Nov 30, 2005 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Parkinson's Disease, this trial is completed. The trial is conducted by Kyowa Kirin Co., Ltd. and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Aug 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyowa Kirin Co., Ltd.

Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan